AsclepiX Therapeutics

ONL Therapeutics

This biopharmaceutical company develops neuroprotective peptide therapies to prevent retinal cell death and preserve vision for patients with retinal diseases and conditions.

Aviceda Therapeutics

This biotechnology firm develops glycan-coated nanoparticle therapeutics to treat geographic atrophy and other inflammatory diseases for patients with vision loss.

Aviceda

This biotechnology company develops nanoparticle glyco-therapeutics for patients with immune-mediated diseases, primarily targeting macular degeneration and other ophthalmic, neurological and inflammatory conditions.

Eyexora

This company develops therapeutics and medical devices for ophthalmic diseases to treat patients with vision-threatening conditions.

ASHVATTHA THERAPEUTICS

This clinical-stage biopharmaceutical company develops targeted nanomedicine therapeutics for patients with inflammatory, neurological, and ophthalmic diseases including age-related macular degeneration.

Iveric Bio

This biopharmaceutical company develops therapeutic treatments for retinal diseases and provides these medicines to patients with age-related macular degeneration and inherited conditions.

Memento Medicines

This biotech company develops biologic therapies for retinal diseases to treat patients with neovascular age-related macular degeneration and diabetic macular edema.

Breye Therapeutics

This biopharmaceutical company develops orally administered medicines for patients with retinal vascular diseases such as diabetic retinopathy and age-related macular degeneration.